Wang, Hao

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine

Cancer Genomics and DiagnosticsPrenatal Screening and Diagnostics

Cited by 5,067

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 2,710

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 2,099

Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells

Sadtler, K., Estrellas, K., Allen, B. W., Wolf, M. T., Fan, H., Tam, A. J., Patel, C. H., Luber, B. S., Wang, H., Wagner, K. R., et al. (2016) · Science

Wound Healing and TreatmentsTissue Engineering and Regenerative Medicine

Cited by 605

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Rugo, H. S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., Trédan, O., Ciruelos, E., Dalenc, F., Gómez Pardo, P., et al. (2023) · The Lancet

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 496

Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic

Tomkovich, S., Dejea, C. M., Winglee, K., Drewes, J. L., Chung, L., Housseau, F., Pope, J. L., Gauthier, J., Sun, X., Mühlbauer, M., et al. (2019) · Journal of Clinical Investigation

Gut microbiota and healthBacterial biofilms and quorum sensing

Cited by 209

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

Stein, J. E., Lipson, E. J., Cottrell, T. R., Forde, P. M., Anders, R. A., Cimino-Mathews, A., Thompson, E. D., Allaf, M. E., Yarchoan, M., Feliciano, J., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 177

PD‐L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation

Rodić, N., Anders, R. A., Eshleman, J. R., Lin, M.-T., Xu, H., Kim, J. H., Beierl, K., Chen, S., Luber, B. S., Wang, H., et al. (2015) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 46

Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma

Christenson, E. S., Lim, S. J., Durham, J., De Jesus-Acosta, A., Bever, K., Laheru, D., Ryan, A., Agarwal, P., Scharpf, R. B., Le, D. T., et al. (2022) · Cancer Research Communications

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 12

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer

Wilbur, H. C., Durham, J. N., Lim, S. J., Purtell, K., Bever, K. M., Laheru, D. A., De Jesus-Acosta, A., Azad, N. S., Wilt, B., Diaz, L. A., et al. (2023) · Cancer Research Communications

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 9